SCHEMBL14728435

SCHEMBL14728435

CC(C)(C)OC(=O)Nc1n[nH]c(O)c1Cc1cccc(Cl)c1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
REN P00797 1/20 0.42
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
LCK P06239 2/20 0.38
DRD2 P14416 5/20 0.38
DRD3 P35462 1/20 0.36
MAPK1 P28482 2/20 0.36
POLB P06746 1/20 0.36
ATM Q13315 1/20 0.36
CDK1 P06493 1/20 0.35
MAPK14 Q16539 1/20 0.35
LMNA P02545 2/20 0.35
GAA P10253 1/20 0.35
HPGD P15428 1/20 0.35
EGFR P00533 1/20 0.35
SRC P12931 1/20 0.35
TSHR P16473 1/20 0.35
P2RX7 Q99572 1/20 0.34
CCNA2 P20248 1/20 0.33
CDK2 P24941 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14720172 0.83 MEN1 (0.40) MEN1KMT2APOLBP2RX7
SCHEMBL14728258 0.80 REN (0.39) RENMEN1KMT2ALCKDRD2
SCHEMBL15844226 0.72 NR3C1 (0.37) MEN1KMT2AMAPK14P2RX7
SCHEMBL14720231 0.70 PNMT (0.43) MEN1KMT2ALMNAGAATSHR
SCHEMBL28146075 0.68 MEN1 (0.60) MEN1KMT2ALCKMAPK1MAPK14
SCHEMBL29168148 0.68 NQO2 (0.57) RENMEN1KMT2ADRD2MAPK1
SCHEMBL647689 0.67 LCK (0.49) RENMEN1KMT2ALCKDRD2
SCHEMBL22249532 0.66 ATR (0.52) LCKDRD2CYP17A1ATR
SCHEMBL30511949 0.66 RAB9A (0.50) MEN1KMT2ALCKPOLBLMNA
SCHEMBL5467365 0.66 RAB9A (0.50) MEN1KMT2ALCKPOLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096605-B2 Pyrazolopyrimidine derivatives as PI3 kinase inhibitors GLAXOSMITHKLINE LLC (US) 2015-08-04 US disclosed
US-9096605-B2 Pyrazolopyrimidine derivatives as PI3 kinase inhibitors GLAXOSMITHKLINE LLC (US) 2015-08-04 US disclosed
US-20140187545-A1 Pyrazolopyrimidine Derivatives As PI3 Kinase Inhibitors GLAXOSMITHKLINE LLC (US) 2014-07-03 US disclosed
US-20140187545-A1 Pyrazolopyrimidine Derivatives As PI3 Kinase Inhibitors GLAXOSMITHKLINE LLC (US) 2014-07-03 US disclosed
WO-2013028263-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140187545-A1 Pyrazolopyrimidine Derivatives As PI3 Kinase Inhibitors PI4KB, PIK3CA, PI4K2B REN 4505/4885MEN1 2967/4885KMT2A 3562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.